Last reviewed · How we verify
NCT06760273
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
trial testing No Intervention: Observational Cohort in Bronchiectasis Adult in 364 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 364 |
| Start date | 16 October 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 58 locations across China |
Drugs / interventions tested
- No Intervention: Observational Cohort — full drug profile →
Conditions studied
- Bronchiectasis Adult — all drugs for Bronchiectasis Adult →
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Who can join
Adults 18 to 80, any sex, with Bronchiectasis Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis. Building on the findings of the initial ERASE study, which evaluated the efficacy and safety of Tobramycin Inhalation Solution, ERASE II aims to determine whether successful PA eradication influences patient prognosis over an extended period. The study will involve a total observation period of 36 months, consisting of the initial 9 months of the ERASE study followed by an additional 27 months of comprehensive follow-up. Key outcomes to be assessed include patients' quality of life, lung function, frequency of pulmonary exacerbations, frequency of hospitalization, and overall treatment costs. Additionally, the study will examine the timing and incidence of any potential reinfections with Pseudomonas aeruginosa.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06760273
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention: Observational Cohort
Trials testing the same drug.
- NCT07284771 — MUSCLE-ML: Multimodal Integration of Muscle Strength, Structure by Machine Learning for Precision Rehabilitation After A · not yet recruiting
- NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07475468 — CP382 - Intermittent Catheter (IC) PRO Panel Plan · not yet recruiting
- NCT07382570 — Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months · not yet recruiting
Other recruiting trials for Bronchiectasis Adult
Currently open trials in the same condition.
- NCT07289100 — Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchie · recruiting
- NCT06900062 — The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping · recruiting
- NCT06820918 — Physiotherapy With Positive Expiratory Pressure (PEP) Bottle in Patients With Bronchiectasis · NA · active not recruiting
- NCT06801327 — Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis · NA · recruiting
- NCT06631261 — Cardiopulmonary Responses to 6-Minute Stepper Test in Bronchiectasis Versus Healthy Controls · recruiting
Other Shanghai Pulmonary Hospital, Shanghai, China trials
Trials by the same sponsor.
- NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
- NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
- NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
- NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06760273 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06760273.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing